Opin­ion: Pric­ing in­fo with new drug ap­provals: Time for trans­paren­cy

For years Con­gress has raised con­cerns with the way some drug­mak­ers pay to de­lay gener­ic ver­sions of their brand­ed block­busters, as well as oth­er patent and ever­green­ing tech­niques to add to their sales of old­er prod­ucts.

These games and oth­er ob­fus­ca­tion tac­tics have long ex­tend­ed to drug pric­ing too. Find­ing in­for­ma­tion on the price of a new drug, or even bet­ter, what some­one will ac­tu­al­ly have to pay out of pock­et for that new drug (which is usu­al­ly not the same as the WAC or list price that’s an­nounced), can be ex­ceed­ing­ly dif­fi­cult to find or un­der­stand. Some­times com­pa­nies will an­nounce the list price for a new drug, but oth­er times that an­nounce­ment will come lat­er, or be buried in an SEC fil­ing, or on­ly dis­cov­er­able pub­licly in a gov­ern­ment data­base years lat­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER